Clinical Trials Directory

Combined F18 and F18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Stanford is now accepting new patients for this trial. Please contact Andrei Iagaru at 650-736-2859 for more information.

Investigator(s):

Phase: N/A

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Patients older than 18-year-old, diagnosed with cancer - Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them

External Links

Explore related trials

Contact information

Primary Contact:

Andrei Iagaru 650-736-2859

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: